APEIRON Biologics AG, based in Vienna, Austria, is a biotech company with a focus on biological and immunological approaches to treat cancer and related conditions. The company was founded by Professor Josef Penninger and became operational in 2006. Apeiron currently employs 30 people and is led by a management team with strong background in drug development, especially in cancer immunotherapy.
Apeiron's lead project APN311, an antibody-based therapy to treat patients suffering from neuroblastoma (a rare childhood cancer) has completed clinical development and is about to be submitted for marketing authorization.
See projects for the present status of Apeiron's portfolio.